Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-SARS-CoV-2 IgG
- Development stage
- Phase 2
- Lead developer
- Kamada
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
anti-SARS-CoV-2 IgG is a human plasma-derived hyperimmune polyclonal immunoglobulin G (IgG) product developed by Kamada in collaboration with Kedrion Biopharma. It is manufactured using Kamada's proprietary plasma purification technology from the convalescent plasma of donors who have recovered from COVID-19. The product contains high titers of neutralizing antibodies against the SARS-CoV-2 virus, specifically targeting the spike protein and other viral antigens to neutralize the virus and prevent severe disease progression. It has been evaluated in clinical trials in Israel, including a Phase 1/2 trial and a Phase 2 randomized open-label trial comparing it to high-titer convalescent plasma in hospitalized patients with moderate to severe COVID-19.
- Other names
- anti-SARS-CoV-2 plasma-derived hyperimmune globulin (IgG)cIgGconvalescent immunoglobulinsKamada COVID-19 IgGKamada anti-SARS-CoV-2 IgGKamada's COVID-19 IgG product
02
Targets
NeuraminidaseFcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ACE2 (Angiotensin-converting enzyme 2)N (Nucleocapsid protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on anti-SARS-CoV-2 IgG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-SARS-CoV-2 IgG.